Editor's note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in ...
ChemoCentryx (CCXI) and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that they had achieved positive results from the phase 3 study treating patients with ANCA-associated ...
-- Primary endpoint achieved: CCX168 demonstrates numerical superiority and achieves statistical significance in test for non-inferiority in BVAS response relative to standard of care -- -- Treatment ...
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- “The vasculitis community is elated that TAVNEOS is now approved, bringing a much-needed new treatment option to ...
Complement activation in patients with AAV who are in remission may be reflective of ongoing renal scarring. Persistent complement activation during disease remission in antineutrophil cytoplasmic ...
Please provide your email address to receive an email when new articles are posted on . SCOTTSDALE, Ariz. — Recent efforts in vasculitis research have seen both “exciting” and “frustrating” results, ...
Gastrointestinal involvement is rare in large-vessel vasculitides and is mainly due to large-vessel stenosis or occlusion, with long-segment gastrointestinal tract ischaemic manifestations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback